List of EyePoint Pharmaceuticals patents

List of EyePoint Pharmaceuticals patents

List of Menasha Corporation patents

List of Cyberlink Corp patents

List of NGM Biopharmaceuticals patents

Waste heat recovery system venture capital investors

List of SBIR/STTR awards granted to Operant Networks

Patents where

Current Assignee

Name

is

EyePoint Pharmaceuticals

	Name	Description	Patent Applicant	Current Assignee	Inventor	Patent Jurisdiction	Patent Number	Date of Patent
	‌ US Patent 11873334 Method of treating ocular conditions by administering an antibody that activates Tie2 and binds VEGF	Patent 11873334 was granted and assigned to EyePoint Pharmaceuticals on January, 2024 by the United States Patent and Trademark Office.	EyePoint Pharmaceuticals	EyePoint Pharmaceuticals		United States Patent and Trademark Office	11873334	January 16, 2024
	‌ US Patent 11413242 Formulations of Tie-2 activators and methods of use thereof	Patent 11413242 was granted and assigned to EyePoint Pharmaceuticals on August, 2022 by the United States Patent and Trademark Office.	EyePoint Pharmaceuticals	EyePoint Pharmaceuticals		United States Patent and Trademark Office	11413242	August 16, 2022
	‌ US Patent 11298323 Bioerodible drug delivery devices		EyePoint Pharmaceuticals	EyePoint Pharmaceuticals		United States Patent and Trademark Office	11298323	April 12, 2022
	‌ US Patent 11180551 Humanized monoclonal antibodies that target VE-PTP (HPTP-beta)	Patent 11180551 was granted and assigned to EyePoint Pharmaceuticals on November, 2021 by the United States Patent and Trademark Office.		EyePoint Pharmaceuticals		United States Patent and Trademark Office	11180551	November 23, 2021
	‌ US Patent D851755 Ocular inserter	Patent D851755 was granted and assigned to EyePoint Pharmaceuticals on June, 2019 by the United States Patent and Trademark Office.	PSivida	EyePoint Pharmaceuticals		United States Patent and Trademark Office	D851755	June 18, 2019
	‌ US Patent 11253502 Tie-2 activators targeting the Schlemm's canal	Patent 11253502 was granted and assigned to EyePoint Pharmaceuticals on February, 2022 by the United States Patent and Trademark Office.	EyePoint Pharmaceuticals	EyePoint Pharmaceuticals		United States Patent and Trademark Office	11253502	February 22, 2022
	‌ US Patent 10300114 Bioerodible sustained release drug delivery systems	Patent 10300114 was granted and assigned to EyePoint Pharmaceuticals on May, 2019 by the United States Patent and Trademark Office.	PSivida	EyePoint Pharmaceuticals		United States Patent and Trademark Office	10300114	May 28, 2019
	‌ US Patent 10363163 Injector apparatus	Patent 10363163 was granted and assigned to EyePoint Pharmaceuticals on July, 2019 by the United States Patent and Trademark Office.	PSivida	EyePoint Pharmaceuticals		United States Patent and Trademark Office	10363163	July 30, 2019
	‌ US Patent 11666558 Methods of treating intraocular pressure with activators of Tie-2		EyePoint Pharmaceuticals	EyePoint Pharmaceuticals		United States Patent and Trademark Office	11666558	June 6, 2023
	‌ US Patent 12064420 Tie-2 activators targeting the Schlemm's canal	Patent 12064420 was granted and assigned to EyePoint Pharmaceuticals on August, 2024 by the United States Patent and Trademark Office.	EyePoint Pharmaceuticals	EyePoint Pharmaceuticals		United States Patent and Trademark Office	12064420	August 20, 2024

10 results

0 selected

10 results

0 selected